Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3740399/
https://ncbi.nlm.nih.gov/pubmed/23364621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.29
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars